What is HC Wainwright’s Forecast for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for Corbus Pharmaceuticals in a research note issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado expects that the biopharmaceutical company will post earnings per share of ($1.58) for the quarter. HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($5.89) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2027 earnings at ($1.52) EPS, Q3 2027 earnings at ($1.52) EPS and Q4 2027 earnings at ($1.52) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.54).

A number of other equities research analysts have also recently commented on the company. Oppenheimer reduced their price objective on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Mizuho set a $33.00 target price on Corbus Pharmaceuticals in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Thursday, October 15th. Finally, Wall Street Zen cut Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $39.57.

Corbus Pharmaceuticals Price Performance

CRBP stock opened at $3.93 on Wednesday. The company’s 50-day moving average is $6.14 and its 200-day moving average is $8.43. Corbus Pharmaceuticals has a 1 year low of $2.81 and a 1 year high of $12.88. The stock has a market capitalization of $73.38 million, a PE ratio of -0.63 and a beta of 2.80.

Insider Activity at Corbus Pharmaceuticals

In related news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the company’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $4.10, for a total value of $1,742,500.00. Following the sale, the insider owned 1,919,971 shares in the company, valued at $7,871,881.10. This represents a 18.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.50% of the stock is currently owned by insiders.

Institutional Trading of Corbus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC raised its stake in shares of Corbus Pharmaceuticals by 8.8% in the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after purchasing an additional 140,000 shares during the last quarter. Exome Asset Management LLC boosted its position in shares of Corbus Pharmaceuticals by 67.8% during the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after buying an additional 94,593 shares during the last quarter. Doliver Advisors LP purchased a new position in shares of Corbus Pharmaceuticals during the third quarter valued at approximately $518,000. Dimensional Fund Advisors LP grew its holdings in Corbus Pharmaceuticals by 76.6% during the first quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock worth $1,281,000 after buying an additional 59,248 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Corbus Pharmaceuticals during the second quarter worth $425,000. 64.64% of the stock is owned by institutional investors.

Trending Headlines about Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target. The analyst expects losses of $1.58 per share in Q1 2027 and $1.52 per share in each of Q2–Q4. The rating and target may provide support, though the estimates still indicate continued losses.
• Negative Sentiment: Corbus reported a Q3 2026 loss of $1.81 per share, missing the consensus estimate of a $1.27 loss by $0.54. The earnings shortfall could pressure the stock. Corbus Q3 2026 press release

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.